Sun Pharmaceutical Industries, announced its release of Leqselvi in the U.S. earlier this week. Leqselvi™ is currently ...

Sun Pharma and Incyte Corporation have settled a legal dispute over Leqselvi, a drug used for severe hair loss. Sun has ...

A new study published in the Journal of American Medical Association showed that individuals with autoimmune skin diseases ...

Leqselvi (deuruxolitinib) 8 mg tablets are approved for adults with severe alopecia areata, a disease that causes the immune system to attack hair follicles, leading to partial or complete hair loss ...

The delay in Sun Pharma's launch of Leqselvi in the US was caused by a patent infringement case, which was later settled in a ...

You might associate autoimmune conditions with symptoms like skin disease, chronic pain, and fatigue. A less-discussed ...

Sun Pharma shares rose nearly 2 per cent on Tuesday after the company launched Leqselvi, a new treatment for severe alopecia ...

Sun Pharmaceutical Industries Limited announced Leqselvi (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the US. Leqselvi is ...

The International Medical Derm Summit 2025 highlighted China's dermatological advancements, fostering global collaboration ...

"The launch of LEQSELVI in the U.S. brings an effective, new treatment option for severe alopecia areata to eligible patients and the healthcare providers who treat them," said Richard Ascroft, CEO, ...

Sun Pharma settles litigation with Incyte over Leqselvi, launches product for severe alopecia areata treatment in the US.

Mumbai: Sun Pharmaceutical Industries Limited has announced the launch of LEQSELVI (deuruxolitinib) 8 mg tablets in the U.S.